Sarah Quirk, PhD

This study seeks to understand the relationship between bolus thickness and dose coverage for the treatment of post-mastectomy breast cancer patients. With the advent of novel bolus materials and 3D printing, it is possible to use bolus with thicknesses outsi...

To quantify organ-at-risk (OAR) sparing achievable using a hybrid approach combining conventional image-guided radiotherapy (IGRT) with a CT-guided online adaptive radiotherapy (CT-ART) cone-down boost for pelvic malignancies.

Peer review is a core component of quality assurance in radiation oncology. This study evaluated whether physician years of clinical experience were associated with differences in peer review change rates within a standardized, prospective, disease-site–speci...

Phase II and III clinical trials establish standards of care in radiation oncology; however, achieving equivalent clinical outcomes in routine practice depends on the reproducible implementation of trial protocols. We systematically evaluated whether publishe...

Clinical Trials Specialty Program

Clinical innovation is essential for advancing radiation therapy and is often led by clinically medical physicists. As the clinical and academic landscape evolves, establishing a research portfolio presents challenges and new opportunities for medical physici...

As artificial intelligence becomes increasingly integral to clinical oncology and clinical trials, medical physicists are uniquely positioned to lead the development of the robust system architectures required to integrate AI safely and effectively. This sess...

Clinical Trials Specialty Program